Healthcare Investment Fund

Managing DirectorContracting and providing sales force distribution to Pre-IPO Start Up VC funded companies to achieve sales and marketing objectives in target markets: Vascular and Endovascular SurgeryMulti-State Sales Distribution Contracts: Biocardia, Inc., ALN, Inc., Angioslide, Inc., Vascular FlowTechnologies, Inc., Asahi-Intecc, Inc., Onset Medical, Inc., (Aquired by Terumo)

Cardiovascular Systems Inc. (CSI) is comprised of a highly experienced, uniquely qualified team of experts experienced in the assessment, development and commercialization of medical devices for treating cardiovascular disease.In 2004, CSI began developing "orbital" technology with the goal of creating smooth, patent lumens in diseased vessels. In the years following, the company refined the technology to address the growing market need of providing a safer more effective atherectomy device, and the chance to shift the treatment paradigm to improve the quality of life for the 12 million Americans who suffer from PAD.

FoxHollow Technologies, Inc. designs, develops, manufactures, and sells medical devices primarily for the treatment of peripheral artery disease (PAD) and other cardiovascular disease. It offers the SilverHawk Plaque Excision System, a minimally-invasive catheter system that treats PAD by removing plaque to reopen narrowed or blocked arteries. The company sells its SilverHawk Plaque Excision System through direct sales force in the United States, principally to interventional cardiologists, vascular surgeons, and interventional radiologists. FoxHollow Technologies also markets the Rinspirator System, which removes thrombi or blood clots from occluded arteries in patients suffering from PAD or coronary artery disease. It has research collaboration with Merck & Co., Inc. to analyze atherosclerotic plaque removed from patient arteries for identifying new biomarkers for atherosclerotic disease progression. As of October 4, 2007 Foxhollow Technologies, Inc. is a subsidiary of ev3, Inc

Cyberonics, Inc. (NASDAQ: CYBX) pioneered the Vagus Nerve Stimulation (VNS Therapy®) System within the Neurology and Neurosurgery markets. Founded to design, develop and market implantable medical devices for the treatment of debilitating neurological disorders. Cyberonics has emerged as a leader in the neuromodulation industry.

National Corporate Sales Trainer/Sales/National AccountsHIV-Oncology Division